AstraZeneca aims to transform cancer outcomes with new data across industry-leading portfolio at ESMO 2022
Results will further underscore efficacy and safety of Imfinzi, Tagrisso and Lynparza across multiple cancers with high unmet need.Enhertu data will reinforce its transformative potential in HER2-targetable cancers.New data for MEDI5752 will advance the science of next-generation immunotherapy.AstraZeneca will present new data supporting its ambition to redefine cancer care at the European Society for Medical Oncology (ESMO) Congress 2022, 9 to 13 September 2022. A total of 15 approved and potential new medicines from AstraZeneca will be featured across more than 75 abstracts in 13